moatshark My

All holdings

Ionis Pharmaceuticals

IONS

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$182m
Combined value at quarter end
Last quarter
1 bought
1 sold or trimmed
Fund portfolios
2
Funds holding it
See which
Price at Q2 ’26 end
$79.29
+5.6% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

-15.9%Q3 ’24
-12.7%Q4 ’24
-13.7%Q1 ’25
+31.0%Q2 ’25
+65.6%Q3 ’25
+20.9%Q4 ’25
-5.1%Q1 ’26
+5.6%Q2 ’26
Q3 ’24: -15.9%; Q4 ’24: -12.7%; Q1 ’25: -13.7%; Q2 ’25: +31.0%; Q3 ’25: +65.6%; Q4 ’25: +20.9%; Q1 ’26: -5.1%; Q2 ’26: +5.6%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
2Q2 ’25
2Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 2; Q2 ’25: 2; Q3 ’25: 2; Q4 ’25: 2; Q1 ’26: 2; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Ionis Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Ionis Pharmaceuticals
Tweedy, Browne13.7%$181m$181mAdded +0.2%18 qtrs
Horizon Kinetics0.0%$865k$865kTrimmed -4.6%30 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Ionis Pharmaceuticals
Bought or soldFiling
16 Oct 2026Devers Shannon L.EVP, Chief Human Resources Ofc▼ Sold1,357$43.54$59kForm 4
16 Oct 2026Swayze EricEVP Research▼ Sold53$43.54$2kForm 4
31 Jul 2026Hayden Michael RDirector▲ Bought5,000$51.60$258kForm 4
30 Jul 2026Hayden Michael RDirector▲ Bought15,000$53.38$801kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Incorporated in
California
Financial year ends
31 December
Shares outstanding
166m at 23 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$147m2013
$284m2015
$514m2017
$1.1bn2019
$810m2021
$788m2023
$944m2025
2013: $147m; 2014: $214m; 2015: $284m; 2016: $373m; 2017: $514m; 2018: $600m; 2019: $1.1bn; 2020: $729m; 2021: $810m; 2022: $587m; 2023: $788m; 2024: $705m; 2025: $944m
Ionis Pharmaceuticals revenue and net income by year
YearRevenueNet income
2025$944m−$381m
2024$705m−$454m
2023$788m−$366m
2022$587m−$270m
2021$810m−$28.6m
2020$729m−$444m
2019$1.1bn$278m
2018$600m$274m
2017$514m$346k
2016$373m−$60.4m
2015$284m−$88.3m
2014$214m−$39.0m
2013$147m−$60.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Ionis Pharmaceuticals, from their latest N-PORT filings.

Funds holding Ionis Pharmaceuticals
Tweedy, Browne International Value FundTweedy, Browne3.3%$138m30 Jun 2026
Tweedy, Browne International Value Fund IITweedy, Browne2.5%$4.0m30 Jun 2026